Merdury Biopharmaceutical

Merdury Biopharmaceutical EBIT Margin

The EBIT Margin (Operating Margin) of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026 is -1,088.90 %. In the previous year, EBIT Margin (Operating Margin) was -4,172.80 % — a change of -73.90% (higher).

EBIT Margin

-1,088.90 %

YoY

-73.90%

Last updated:

EBIT Margin (Operating Margin) of Merdury Biopharmaceutical is 2024 -1,088.90 % . EBIT Margin (Operating Margin) of Merdury Biopharmaceutical was 2023 -4,172.80 % . It decreases by -73.90% higher compared to the previous year.

Merdury Biopharmaceutical's operating (EBIT) margin stands at -1,088.9%, up from -1,151.1% several years earlier.

The Merdury Biopharmaceutical EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2022
-1,151.12 TWD
Jan 1, 2023
-4,172.80 TWD
Jan 1, 2024
-1,088.90 TWD
The Merdury Biopharmaceutical EBIT Margin history
YEAREBIT MarginYoY
-1,088.90 %-73.90%
-4,172.80 %+262.50%
-1,151.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

EBIT Margin (Operating Margin) of Merdury Biopharmaceutical is -1,088.90 % in 2024.

EBIT Margin (Operating Margin) of Merdury Biopharmaceutical changed from -4,172.80 % to -1,088.90 %, representing a -73.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Merdury Biopharmaceutical

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Merdury Biopharmaceutical